ReviewReviews in endocrine & metabolic disorders2026
LEAP2 as a therapeutic target in obesity and cardiometabolic disorders.
Review in Reviews in endocrine & metabolic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The evolving landscape of obesity pharmacotherapy.Nature reviews. Drug discovery · 2026Review
- The Ghrelin-LEAP2 System in Obesity and Diabetes: Pathophysiological Roles and Therapeutic Potential.Current obesity reports · 2026Review
- Hypothalamic wars: the last nanodelivery.Reviews in endocrine & metabolic disorders · 2026Review
- Hypothalamus-liver talks: whispers in the language of metabolism.Reviews in endocrine & metabolic disorders · 2026Review
- The gut-brain axis in avian appetite regulation: Integrating peripheral signals with central neurocircuitry.Poultry science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a global public health challenge intimately linked to cardiometabolic complications. Although current anti-obesity medications can produce substantial and rapid weight loss, their discontinuation often results in rapid weight regain, underscoring the urgent need for therapies that support long-term weight loss maintenance. The ghrelin receptor system, comprising the hormone ghrelin and its receptor growth hormone secretagogue receptor 1a (GHSR1a), has long been a target for appetite regulation, but decades of drug development have yielded limited clinical success. The recent discovery of liver-expressed antimicrobial peptide 2 (LEAP2), an endogenous GHSR1a antagonist and inverse agonist, has reignited interest in this pathway. LEAP2 suppresses appetite in both rodents and humans, and optimized analogs have shown modest but promising metabolic effects in preclinical models. Although less potent than currently leading agents, LEAP2-based therapies may offer value as adjunct treatments, particularly for sustaining weight loss. This review explores the evolving therapeutic potential of the GHSR1a pathway, with a particular focus on LEAP2 as a novel strategy for treating obesity and associated cardiometabolic disorders.
Indexed as
Identifiers
41284160What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.